{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:08:26Z","timestamp":1793102906530,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eururo.2022.12.021","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:23:09Z","timestamp":1672860189000},"page":"241-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention"],"prefix":"10.1016","volume":"83","author":[{"given":"Tyler M.","family":"Seibert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla P.","family":"Garraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Plym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle F.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Helfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind A.","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.12.021_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0015","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1001\/jamaoncol.2020.4922","article-title":"Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0020","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0030","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1016\/j.csbj.2021.06.040","article-title":"A survey of direct-to-consumer genotype data, and quality control tool (GenomePrep) for research","volume":"19","author":"Lu","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.eururo.2022.12.021_b0035","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0040","doi-asserted-by":"crossref","unstructured":"R.A. Eeles H. Ni Raghallaigh The BARCODE1 Study Group. BARCODE 1: a pilot study investigating the use of genetic profiling to identify men in the general population with the highest risk of prostate cancer to invite for targeted screening. J Clin Oncol 2020;38:1505\u20135.","DOI":"10.1200\/JCO.2020.38.15_suppl.1505"},{"key":"10.1016\/j.eururo.2022.12.021_b0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2021.12.023","article-title":"A rare germline HOXB13 variant contributes to risk of prostate cancer in men of African ancestry","volume":"81","author":"Darst","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0060","doi-asserted-by":"crossref","first-page":"80.e1","DOI":"10.1016\/j.urolonc.2019.09.010","article-title":"Ethnic disparities among men with prostate cancer undergoing germline testing","volume":"38","author":"Kwon","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0070","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0075","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0080","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2016.69.4935","article-title":"Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores","volume":"35","author":"Lecarpentier","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0085","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0095","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0100","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0105","unstructured":"Moses KA, et al. NCCN guidelines: prostate cancer early detection. Version 1.2022. Vol. 69. 2022."},{"key":"10.1016\/j.eururo.2022.12.021_b0110","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0115","unstructured":"Schaeffer EM, et al. NCCN guidelines: prostate cancer. Version 4.2022. 2022."},{"key":"10.1016\/j.eururo.2022.12.021_b0120","unstructured":"Daly MB, et al. NCCN guidelines: genetic\/familial high-risk assessment: breast, ovarian, and pancreas. Version 2.2022. 2022."},{"key":"10.1016\/j.eururo.2022.12.021_b0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/OP.20.00431","article-title":"Practical considerations and challenges for germline genetic testing in patients with prostate cancer: recommendations from the Germline Genetics Working Group of the PCCTC","volume":"16","author":"Szymaniak","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eururo.2022.12.021_b0135","article-title":"Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts","volume":"360","author":"Seibert","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2022.12.021_b0140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2020.11.014","article-title":"Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis","volume":"79","author":"Shi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jnci\/djab058","article-title":"Evaluation of a multiethnic polygenic risk score model for prostate cancer","volume":"114","author":"Plym","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2022.12.021_b0160","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41467-021-21287-0","article-title":"Polygenic hazard score is associated with prostate cancer in multi-ethnic populations","volume":"12","author":"Huynh-Le","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2022.12.021_b0165","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41391-022-00497-7","article-title":"Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score","volume":"25","author":"Huynh-Le","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.12.021_b0170","doi-asserted-by":"crossref","unstructured":"Pagadala MS, et al. Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. JNCI J Natl Cancer Inst. In press. https:\/\/doi.org\/10.1093\/jnci\/djac199.","DOI":"10.1093\/jnci\/djac199"},{"key":"10.1016\/j.eururo.2022.12.021_b0175","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1158\/1055-9965.EPI-19-1527","article-title":"A genetic risk score to personalize prostate cancer screening, applied to population data","volume":"29","author":"Huynh-Le","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2022.12.021_b0180","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41591-019-0579-z","article-title":"Genome-wide germline correlates of the epigenetic landscape of prostate cancer","volume":"25","author":"Houlahan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0185","article-title":"Genetic factors associated with prostate cancer conversion from active surveillance to treatment","volume":"3","author":"Jiang","year":"2022","journal-title":"Hum Genet Genomics Adv"},{"key":"10.1016\/j.eururo.2022.12.021_b0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2022.12.021_b0195","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2","article-title":"Independent origin of multiple foci of prostatic intraepithelial neoplasia","volume":"83","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pros.24140","article-title":"Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients","volume":"81","author":"Xu","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2022.12.021_b0205","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/cncr.20243","article-title":"Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate","volume":"100","author":"Arora","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","article-title":"Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue","volume":"47","author":"Cooper","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2021.12.011","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort","volume":"82","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0225","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.clgc.2021.11.009","article-title":"Helix: a digital tool to address provider needs for prostate cancer genetic testing in clinical practice","volume":"20","author":"Giri","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0230","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41391-021-00341-4","article-title":"Common genetic and clinical risk factors: association with fatal prostate cancer in the cohort of Swedish men","volume":"24","author":"Huynh-Le","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.12.021_b0235","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pros.23200","article-title":"Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: results from the prostate cancer prevention trial","volume":"76","author":"Chen","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2022.12.021_b0240","first-page":"211","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2022.12.021_b0245","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/cncr.30687","article-title":"Is prostate cancer different in black men? Answers from 3 natural history models","volume":"123","author":"Tsodikov","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0250","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.urology.2014.05.009","article-title":"Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups","volume":"84","author":"Mahal","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2022.12.021_b0255","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cncr.33224","article-title":"Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration","volume":"127","author":"McKay","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41391-021-00403-7","article-title":"Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24","volume":"25","author":"Karunamuni","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.12.021_b0270","doi-asserted-by":"crossref","first-page":"pkab097","DOI":"10.1093\/jncics\/pkab097","article-title":"DNA repair pathways and their association with lethal prostate cancer in African American and European American men","volume":"6","author":"Plym","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eururo.2022.12.021_b0275","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.eururo.2020.04.060","article-title":"A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry","volume":"78","author":"Darst","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0280","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.12.021_b0285","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/s41467-019-11112-0","article-title":"Analysis of polygenic risk score usage and performance in diverse human populations","volume":"10","author":"Duncan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2022.12.021_b0290","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ijc.33282","article-title":"African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer","volume":"148","author":"Karunamuni","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0295","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2022.12.021_b0300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2021.04.013","article-title":"Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk","volume":"80","author":"Darst","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0305","doi-asserted-by":"crossref","unstructured":"Plym A, et al. A healthy lifestyle in men at increased genetic risk for prostate cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.008.","DOI":"10.1016\/j.eururo.2022.05.008"},{"key":"10.1016\/j.eururo.2022.12.021_b0310","unstructured":"Pagadala M, et al. Healthy lifestyle and Agent Orange exposure modulate inherited prostate cancer risk: an analysis of the Million Veteran Program. 2022. http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.07.09.22277437."},{"key":"10.1016\/j.eururo.2022.12.021_b0315","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0320","doi-asserted-by":"crossref","first-page":"e000339","DOI":"10.1136\/bmjgast-2019-000339","article-title":"Combined effect of modifiable and non-modifiable risk factors for colorectal cancer risk in a pooled analysis of 11 population-based studies","volume":"6","author":"Wang","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.eururo.2022.12.021_b0325","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jnci\/djz241","article-title":"Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK Biobank","volume":"112","author":"Arthur","year":"2020","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2022.12.021_b0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1215932","article-title":"Long-term survival of participants in the prostate cancer prevention trial","volume":"369","author":"Thompson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0335","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.12.021_b0340","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41391-019-0181-y","article-title":"Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT","volume":"23","author":"Ahmed","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.12.021_b0345","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cncr.32702","article-title":"Age dependence of modern clinical risk groups for localized prostate cancer\u2014a population-based study","volume":"126","author":"Huynh-Le","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0350","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/pros.24172","article-title":"Barriers and facilitators of germline genetic evaluation for prostate cancer","volume":"81","author":"Loeb","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2022.12.021_b0355","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1097\/JU.0000000000002545.03","article-title":"PD13-03 Lack of awareness and underutilization of genetic testing in prostate cancer","volume":"207","author":"Thakker","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.12.021_b0360","doi-asserted-by":"crossref","first-page":"106821","DOI":"10.1016\/j.cct.2022.106821","article-title":"Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing","volume":"119","author":"Loeb","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eururo.2022.12.021_b0365","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.bjc.6600008","article-title":"A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes","volume":"86","author":"Antoniou","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2022.12.021_b0370","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","article-title":"A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk","volume":"65","author":"Karlsson","year":"2014","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822028706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822028706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:12:41Z","timestamp":1759583561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822028706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0302283822028706"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.12.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}